Mirae Asset Global Investments Co. Ltd. raised its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 12.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,343 shares of the pharmacy operator's stock after purchasing an additional 16,698 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in CVS Health were worth $10,027,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. LaFleur & Godfrey LLC lifted its stake in shares of CVS Health by 49.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator's stock valued at $217,000 after purchasing an additional 1,610 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of CVS Health in the fourth quarter worth about $5,544,000. Versor Investments LP boosted its stake in shares of CVS Health by 55.9% during the 4th quarter. Versor Investments LP now owns 9,200 shares of the pharmacy operator's stock worth $413,000 after acquiring an additional 3,300 shares in the last quarter. SVB Wealth LLC acquired a new position in shares of CVS Health during the 4th quarter valued at about $1,775,000. Finally, Fisher Asset Management LLC raised its stake in shares of CVS Health by 10.9% in the 4th quarter. Fisher Asset Management LLC now owns 81,561 shares of the pharmacy operator's stock valued at $3,661,000 after acquiring an additional 8,004 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
CVS has been the topic of several analyst reports. Robert W. Baird increased their price target on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Barclays set a $79.00 price target on shares of CVS Health and gave the company an "overweight" rating in a report on Monday, June 2nd. Jefferies Financial Group lifted their price objective on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Cowen restated a "buy" rating on shares of CVS Health in a research note on Monday, May 5th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and an average target price of $75.06.
View Our Latest Analysis on CVS
Insiders Place Their Bets
In other news, Director Guy P. Sansone bought 1,570 shares of the stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the purchase, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This represents a 15.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 1.22% of the stock is owned by company insiders.
CVS Health Price Performance
Shares of CVS traded up $0.78 during trading hours on Friday, hitting $67.38. The stock had a trading volume of 3,770,987 shares, compared to its average volume of 10,832,881. The stock has a market capitalization of $85.23 billion, a price-to-earnings ratio of 16.08, a P/E/G ratio of 0.97 and a beta of 0.57. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. The company's fifty day moving average is $65.06 and its two-hundred day moving average is $61.31. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. The company's quarterly revenue was up 7.0% compared to the same quarter last year. On average, analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Recommended Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
